Han-Kang KY Secures Strategic Investment from OrbiMed, to List on Innovation Board on the 29th

Central News Agency, Taipei, 26th. Han-Kang KY, a company focused on drug development, announced that its IPO book-building process has been completed, with the offering price set at NT$120 per share. The fundraising round attracted domestic and international institutional investors, including a strategic investment from OrbiMed, a global healthcare fund managing over $10 billion. The company is scheduled to list on the Innovation Board on the 29th. Han-Kang stated that it issued 9,400 new shares, with 10% reserved for employees and the remaining 8,460 shares offered through book-building. Due to oversubscription, the final price was set at NT$120. OrbiMed invests in biopharmaceuticals, medical devices, diagnostics, and digital health, and its participation highlights the international potential of Han-Kang's protein platform. Following this round, the company holds nearly $140 million (approx. NT$4.5 billion) in cash and credit lines, sufficient to support clinical trials and global licensing activities for several years. Chairman Liu Shih-kao stated that as the pharmaceutical industry faces a 'patent cliff,' Han-Kang aims to leverage its clinical data to drive international licensing and commercial partnerships.